Elamin H Elbasha

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Model for assessing human papillomavirus vaccination strategies
    Elamin H Elbasha
    Merck Research Laboratories, North Wales, Pennsylvania 19454 1099, USA
    Emerg Infect Dis 13:28-41. 2007
  2. ncbi Deadweight loss of bacterial resistance due to overtreatment
    Elamin H Elbasha
    US Centers for Disease Control and Prevention, Atlanta 30341, USA
    Health Econ 12:125-38. 2003
  3. ncbi Global stability of equilibria in a two-sex HPV vaccination model
    Elamin H Elbasha
    Merck Research Laboratories, UG1C 60, P O Box 1000, North Wales, PA 19454 1099, USA
    Bull Math Biol 70:894-909. 2008
  4. ncbi Structural differences among cost-effectiveness models of human papillomavirus vaccines
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Expert Rev Vaccines 7:895-913. 2008
  5. ncbi Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale
    Elamin H Elbasha
    US Centers for Disease Control and Prevention, USA
    Health Econ 13:21-35. 2004
  6. ncbi Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in portugal
    Elamin H Elbasha
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    Appl Health Econ Health Policy 11:65-78. 2013
  7. ncbi Theoretical assessment of public health impact of imperfect prophylactic HIV-1 vaccines with therapeutic benefits
    Elamin H Elbasha
    Merck Research Laboratories, 10 Sentry Parkway, BL 2 3, Blue Bell, PA 19422, USA
    Bull Math Biol 68:577-614. 2006
  8. ncbi A multi-type HPV transmission model
    Elamin H Elbasha
    Merck Research Laboratories, UG1C 60, PO Box 1000, North Wales, PA 19454 1099, USA
    Bull Math Biol 70:2126-76. 2008
  9. ncbi Vaccination against multiple HPV types
    Elamin H Elbasha
    Merck Research Laboratories, 10 Sentry Parkway, BL 2 3, Blue Bell, PA 19422, United States
    Math Biosci 197:88-117. 2005
  10. ncbi Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach
    Elamin H Elbasha
    US Centers for Disease Control and Prevention, USA
    Health Econ 14:457-70. 2005

Detail Information

Publications25

  1. ncbi Model for assessing human papillomavirus vaccination strategies
    Elamin H Elbasha
    Merck Research Laboratories, North Wales, Pennsylvania 19454 1099, USA
    Emerg Infect Dis 13:28-41. 2007
    ..The ICER of this strategy was $45,056 per QALY...
  2. ncbi Deadweight loss of bacterial resistance due to overtreatment
    Elamin H Elbasha
    US Centers for Disease Control and Prevention, Atlanta 30341, USA
    Health Econ 12:125-38. 2003
    ..The annual deadweight loss associated with outpatient prescriptions for amoxicillin in the United States is estimated at US dollars 225 million...
  3. ncbi Global stability of equilibria in a two-sex HPV vaccination model
    Elamin H Elbasha
    Merck Research Laboratories, UG1C 60, P O Box 1000, North Wales, PA 19454 1099, USA
    Bull Math Biol 70:894-909. 2008
    ..If the effective reproduction number is less than unity, the infection-free equilibrium is globally asymptotically stable, and HPV will be eliminated...
  4. ncbi Structural differences among cost-effectiveness models of human papillomavirus vaccines
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Expert Rev Vaccines 7:895-913. 2008
    ....
  5. ncbi Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale
    Elamin H Elbasha
    US Centers for Disease Control and Prevention, USA
    Health Econ 13:21-35. 2004
    ..We derive the optimal decision rules under variable returns to scale using optimization techniques, and employ several examples to illustrate the concepts and methods...
  6. ncbi Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in portugal
    Elamin H Elbasha
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    Appl Health Econ Health Policy 11:65-78. 2013
    ..The recent approval of two protease inhibitors, boceprevir and telaprevir, is likely to change the management of chronic hepatitis C virus (HCV) genotype 1 infection...
  7. ncbi Theoretical assessment of public health impact of imperfect prophylactic HIV-1 vaccines with therapeutic benefits
    Elamin H Elbasha
    Merck Research Laboratories, 10 Sentry Parkway, BL 2 3, Blue Bell, PA 19422, USA
    Bull Math Biol 68:577-614. 2006
    ....
  8. ncbi A multi-type HPV transmission model
    Elamin H Elbasha
    Merck Research Laboratories, UG1C 60, PO Box 1000, North Wales, PA 19454 1099, USA
    Bull Math Biol 70:2126-76. 2008
    ....
  9. ncbi Vaccination against multiple HPV types
    Elamin H Elbasha
    Merck Research Laboratories, 10 Sentry Parkway, BL 2 3, Blue Bell, PA 19422, United States
    Math Biosci 197:88-117. 2005
    ..We show that if interactions among HPV types are synergistic, mass vaccination may reduce the prevalence of types that are not even included in the vaccine...
  10. ncbi Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach
    Elamin H Elbasha
    US Centers for Disease Control and Prevention, USA
    Health Econ 14:457-70. 2005
    ..An empirical example to illustrate the methods and concepts is provided...
  11. ncbi Age-based programs for vaccination against HPV
    Elamin H Elbasha
    Merck Research Laboratories, Merck and Co, Inc, NorthWales, PA, USA
    Value Health 12:697-707. 2009
    ..Answering the question of which age groups are appropriate to target for catch-up vaccination with the newly licensed quadrivalent HPV vaccine (types 6/11/16/18) will be important for developing vaccine policy recommendations...
  12. ncbi Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation
    Ralph P Insinga
    Department of Health Economic Statistics UG1C 60, Merck Research Laboratories, PO Box 1000, North Wales, PA 19454 1099, USA
    Vaccine 26:128-39. 2007
    ..S.) per quality-adjusted life year (QALY) gained for female vaccination strategies to approximately 16000 dollars /QALY for adding male vaccination with catch-up...
  13. ncbi Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease
    Erik J Dasbach
    Merck Research Laboratories, Blue Bell, PA, USA
    Epidemiol Rev 28:88-100. 2006
    ....
  14. ncbi Impact of vaccinating boys and men against HPV in the United States
    Elamin H Elbasha
    Health Economic Statistics, Biostatistics and Research Decision Sciences, Merck Research Laboratories, Merck and Co, Inc, UG1C 60, PO Box 1000, North Wales, PA 19454 1099, USA elamin
    Vaccine 28:6858-67. 2010
    ..Vaccinating boys and men age 9-26 against all HPV 6/11/16/18-associated diseases provides substantial public health benefits and is cost-effective at commonly cited thresholds...
  15. ncbi The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan
    Erik J Dasbach
    Health Economic Statistics, Biostatistics and Research Decision Sciences, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Asian Pac J Cancer Prev 9:459-66. 2008
    ....
  16. ncbi Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA, USA
    BMC Infect Dis 9:119. 2009
    ..S. population context; (2) Identify areas where additional studies are particularly needed...
  17. ncbi The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary
    Erik J Dasbach
    Health Economic Statistics, Biostatistics and Research Decision Sciences, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    J Med Econ 13:110-8. 2010
    ....
  18. ncbi Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Cancer Epidemiol Biomarkers Prev 16:709-15. 2007
    ..To estimate the incidence and duration of cervical human papillomavirus (HPV)-6, HPV-11, HPV-16, and HPV-18 infections in a population of young American women...
  19. ncbi Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women
    Ralph P Insinga
    Merck Research Laboratories, North Wales, PA 19454 10099, USA
    Cancer Epidemiol Biomarkers Prev 19:1585-94. 2010
    ..We describe the incidence and duration of cervical human papillomavirus (HPV) infection episodes along with the risk of infection reappearance following a period of nondetection...
  20. ncbi Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, Blue Bell, PA 19422, USA
    Pharmacoeconomics 23:1107-22. 2005
    ....
  21. ncbi The decision to conduct a head-to-head comparative trial: a game-theoretic analysis
    Edward C Mansley
    Outcomes Research and Management, Merck and Co Inc, WP39 166, P O Box 4, West Point, PA 19486 000, USA
    Med Decis Making 27:364-79. 2007
    ..Finally, the results indicate that incentives that offset the direct cost of a trial can prevent a no-trial equilibrium, even when both firms face the possibility of an inferior outcome...
  22. ncbi Preferences and person trade-offs: forcing consistency or inconsistency in health-related quality of life measures?
    Edward C Mansley
    Us centers for Disease Control and Prevention CDC, USA
    Health Econ 12:187-98. 2003
    ..We then discuss preference characterizations in the existing person trade-off literature, from which this relationship may have been derived...
  23. ncbi Cost-effectiveness of raltegravir in HIV/AIDS
    Mohammad Ashraf Chaudhary
    Merck and Co, Inc, UG1C 60, 351 N Sumneytown Pike, PO Box 1000, North Wales, PA 19454 2505, USA
    Expert Rev Pharmacoecon Outcomes Res 11:627-39. 2011
    ..Nonetheless, raltegravir remained cost effective under most scenarios...
  24. ncbi Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model
    Erik J Dasbach
    Health Economic Statistics, Biostatistics and Research Decision Sciences, Merck Research Laboratories, UG1C 60, PO Box 1000, North Wales, PA 19454 1099, USA
    Expert Rev Pharmacoecon Outcomes Res 8:491-500. 2008
    ....
  25. ncbi Vaccination and the evolutionary ecology of human papillomavirus
    Eric M Poolman
    Department of Epidemiology and Public Health, Yale University School of Medicine, 60 College Street, New Haven, CT 06520 8034, USA
    Vaccine 26:C25-30. 2008
    ..If natural infection provides greater cross-immunity than vaccination, vaccination may expand available niche space up to 470-fold. The balance of epidemiologic data suggests vaccination will reduce the available niche space...